EFFICACY AND GASTROINTESTINAL TOLERABILITY OF BETA-CYCLODEXTRIN-PIROXICAM AND TENOXICAM IN THE TREATMENT OF CHRONIC OSTEOARTHRITIS

  • 1 November 1990
    • journal article
    • research article
    • Vol. 12  (6) , 547-555
Abstract
Thirty patients aged 26 to 70 years with a history of chronic osteoarthritis of at least eight years were randomly assigned to receive 20 mg daily of beta-cyclodextrin-piroxicam (beta-CDP) or tenoxicam for eight weeks. Both drugs effectively reduced pain, inflammation, and functional limitations of the affected joints. Endoscopy revealed minor posttreatment hemorrhagic lesions and erosions; these tended to be less severe in the group treated with beta-CDP than with tenoxicam. Slight to moderate gastrointestinal symptoms were reported by one patient treated with beta-CDP and three patients treated with tenoxicam; the symptoms were poorly correlated with endoscopic findings. It is concluded that both drugs are safe and effective in the control of symptoms in patients with chronic osteoarthritis.

This publication has 0 references indexed in Scilit: